A study of the effect of Alpha lipoic acid in addition to the usual treatment drug in schizophrenia patients
- Conditions
- Health Condition 1: F209- Schizophrenia, unspecified
- Registration Number
- CTRI/2023/12/060745
- Lead Sponsor
- Dr Ramya R
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Schizophrenia diagnosis made by research psychiatrists using the Structured Clinical Interview, SCID-5, for Diagnostic and Statistical Manual of Mental Disorders of more than 2 years duration and on treatment
2)Cognitive symptoms despite adequate antipsychotic treatment assessed by MOCA scored < 26
3)Age 18-60 years of either gender
4)Willing to participate
1)6-months history of any drug or alcohol abuse or dependence
2)Changes in psychotropic medications within the last 4 weeks and patients on valproate use (potential interaction with ALA)
3)Women who are planning to become pregnant, are pregnant, or are breastfeeding
4)Known chronic infections such as HIV or hepatitis C, and liver or renal failure that could adversely impact on patient outcome
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method